Valeant is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in more than 100 countries.
Valeant’s strategy is to focus the business on core geographies and therapeutic classes that offer attractive growth opportunities. Another critical strategic element is business development. Valeant has completed numerous transactions over the past few years to expand its portfolio offering and geographic footprint, including, among others, the acquisitions of Bausch & Lomb and Medicis Pharmaceutical Corporation. It will continue to pursue value-added business development opportunities as they arise.
Valeant’s strategic markets are primarily in the United States, Canada, Europe the Middle East, Latin America, Asia Pacific and Africa. Headquartered in Laval, Quebec, Valeant has approximately 15,000 employees worldwide.
Our most important objective is to serve our stakeholders, including the patients and consumers who use our products, the physicians who prescribe/recommend them, and the customers who provide retail outlets for these products.
We drive performance and take responsibility to deliver on our duties and promises to our stakeholders.
We work best as a lean, high-performing workforce and invest in resources only where it makes business sense to do so
We constantly search for new ways to do things better while creating value
We make decisions and work quickly without sacrificing execution
We share information openly and communicate directly
We strive to build the best team in the industry by investing in one another
VALEANT PHARMACEUTICALS AGREES TO ACQUIRE AMOUN PHARMACEUTICAL
Valeant Europe signed distribution, license rights and supply agreement with Medicem International
Valeant Europe, Middle East & North Africa acquires assets from the Zaraccom Focus Force line of intraocular lenses (IOLs) targeting cost…
Valeant Europe, Middle East & North Africa acquires MedPharma, targeting major therapeutic segment including anti-infective, cardiovascular…
Valeant Europe Acquires Ophthalmology and Orthopedic Brands from CROMA-PHARMA in Western Europe
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million